(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Arcturus Therapeutics, Aspen Group, and Target Corporation.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Arcturus Therapeutics (ARCT)	23.88	23.09%	2023-11-15 12:15:37
2	Aspen Group (ASPU)	0.18	19.33%	2023-11-15 12:15:40
3	Target Corporation (TGT)	129.25	16.66%	2023-11-15 12:22:17
4	Ebix (EBIX)	4.17	16.02%	2023-11-15 12:11:50
5	Harmony Gold Mining Company Limited (HMY)	5.41	14.38%	2023-11-15 07:41:05
6	Hudson Pacific Properties (HPP)	5.67	14.08%	2023-11-15 08:23:07
7	Hannon Armstrong Sustainable Infrastructure Capital (HASI)	22.50	13.64%	2023-11-15 05:09:05
8	V.F. Corporation (VFC)	17.50	12.4%	2023-11-15 12:22:33
9	MicroVision (MVIS)	2.39	11.68%	2023-11-15 12:13:43
10	Catalent (CTLT)	39.51	11.22%	2023-11-15 12:19:12

The three biggest losers today are Eli Lilly and Company, TJX Companies, and Ivy High Income Opportunities Fund.

Rank	Financial Asset	Price	Change	Updated (EST)
1	Eli Lilly and Company (LLY)	587.33	-3.85%	2023-11-15 12:56:20
2	TJX Companies (TJX)	88.96	-3.83%	2023-11-15 12:22:19
3	Ivy High Income Opportunities Fund (IVH)	11.18	-3.54%	2023-11-15 13:43:05
4	Vertex Pharmaceuticals (VRTX)	357.16	-3.46%	2023-11-15 12:51:16
5	Sumitomo Mitsui (SMFG)	9.48	-3.03%	2023-11-15 12:58:38
6	Full House Resorts (FLL)	5.01	-2.72%	2023-11-15 12:12:21
7	Zai Lab (ZLAB)	27.58	-2.7%	2023-11-15 12:52:00
8	BeiGene (BGNE)	196.37	-2.58%	2023-11-15 12:15:42
9	AMC (AMC)	7.86	-2.55%	2023-11-15 12:18:09
10	Novo Nordisk A/S (NVO)	96.68	-2.54%	2023-11-15 12:21:26

Winners today

1. Arcturus Therapeutics (ARCT) – 23.09%

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.

NASDAQ ended the session with Arcturus Therapeutics rising 23.09% to $23.88 on Thursday, following the last session’s upward trend. NASDAQ rose 0.07% to $14,103.84, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Arcturus Therapeutics has a trailing twelve months EPS of $3.03.

PE Ratio

Arcturus Therapeutics has a trailing twelve months price to earnings ratio of 7.88. Meaning, the purchaser of the share is investing $7.88 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.22%.

Volatility

Arcturus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.15%, a negative 1.26%, and a positive 2.90%.

Arcturus Therapeutics’s highest amplitude of average volatility was 4.07% (last week), 3.26% (last month), and 2.90% (last quarter).

More news about Arcturus Therapeutics.

2. Aspen Group (ASPU) – 19.33%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group rising 19.33% to $0.18 on Thursday, following the last session’s downward trend. NASDAQ rose 0.07% to $14,103.84, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

More news about Aspen Group.

3. Target Corporation (TGT) – 16.66%

Target Corporation operates as a general merchandise retailer in the United States. The company offers apparel for women, men, boys, girls, toddlers, and infants and newborns, as well as jewelry, accessories, and shoes; and beauty and personal care, baby gear, cleaning, paper products, and pet supplies. It also provides dry grocery, dairy, frozen food, beverages, candy, snacks, deli, bakery, meat, and food service; electronics, which includes video game hardware and software, toys, entertainment, sporting goods, and luggage; and furniture, lighting, storage, kitchenware, small appliances, home décor, bed and bath, home improvement, school/office supplies, greeting cards and party supplies, and other seasonal merchandise. In addition, the company sells merchandise through periodic design and creative partnerships, and shop-in-shop experience; and in-store amenities. Further, it sells its products through its stores; and digital channels, including Target.com. Target Corporation was incorporated in 1902 and is headquartered in Minneapolis, Minnesota.

NYSE ended the session with Target Corporation rising 16.66% to $129.25 on Thursday, after two successive sessions in a row of gains. NYSE rose 0.2% to $15,763.72, after three successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Target Corporation has a trailing twelve months EPS of $7.29.

PE Ratio

Target Corporation has a trailing twelve months price to earnings ratio of 17.73. Meaning, the purchaser of the share is investing $17.73 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.87%.

More news about Target Corporation.

4. Ebix (EBIX) – 16.02%

Ebix, Inc., together with its subsidiaries, provides on-demand infrastructure software exchanges and e-commerce services to the insurance, financial, travel, cash remittance, and healthcare industries in the United States and internationally. The company develops and deploys insurance and reinsurance exchanges on an on-demand basis using software-as-a-service (SaaS) enterprise solutions in the areas of customer relationship management, front-end and back-end systems, and outsourced administrative and risk compliance solutions. Its EbixCash exchange related products and services include gift cards; travel exchanges services; money transfer services; foreign exchange and outward remittance services; consumer payment services; and on-demand technology to various providers in the areas of lending, wealth and asset management, and travel. The company's insurance exchanges related products and services include SaaS platform and related services; licensing of software; and professional services comprising setup, customization, training, or consulting. Its risk compliance services cover certificates of insurance creation and tracking; consulting services, such as project management, integration, development, and testing; and business process outsourcing services, including domain intensive project management, system consulting services, and claims adjudication/settlement services. The company was formerly known as Delphi Systems, Inc. and changed its name to Ebix, Inc. in December 2003. Ebix, Inc. was founded in 1976 and is headquartered in Johns Creek, Georgia.

NASDAQ ended the session with Ebix jumping 16.02% to $4.17 on Thursday, following the last session’s upward trend. NASDAQ rose 0.07% to $14,103.84, following the last session’s upward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Ebix has a trailing twelve months EPS of $1.09.

PE Ratio

Ebix has a trailing twelve months price to earnings ratio of 3.82. Meaning, the purchaser of the share is investing $3.82 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.64%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Dec 1, 2022, the estimated forward annual dividend rate is 0.3 and the estimated forward annual dividend yield is 8.44%.

Yearly Top and Bottom Value

Ebix’s stock is valued at $4.17 at 01:32 EST, way below its 52-week high of $32.87 and way higher than its 52-week low of $3.14.

Volatility

Ebix’s last week, last month’s, and last quarter’s current intraday variation average was a negative 14.00%, a negative 3.44%, and a positive 5.15%.

Ebix’s highest amplitude of average volatility was 14.00% (last week), 6.94% (last month), and 5.15% (last quarter).

More news about Ebix.

5. Harmony Gold Mining Company Limited (HMY) – 14.38%

Harmony Gold Mining Company Limited engages in the exploration, extraction, and processing of gold. It also explores for uranium, silver, copper, and molybdenum deposits. The company has nine underground operations in the Witwatersrand Basin; an open-pit mine on the Kraaipan Greenstone Belt; and various surface treatment operations in South Africa. It also owns interests in the Hidden Valley, an open-pit gold and silver mine; and Wafi-Golpu, a project in Morobe Province in Papua New Guinea. The company was incorporated in 1950 and is headquartered in Randfontein, South Africa.

NYSE ended the session with Harmony Gold Mining Company Limited rising 14.38% to $5.41 on Thursday, after two sequential sessions in a row of gains. NYSE jumped 0.2% to $15,763.72, after three consecutive sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Harmony Gold Mining Company Limited has a trailing twelve months EPS of $0.42.

PE Ratio

Harmony Gold Mining Company Limited has a trailing twelve months price to earnings ratio of 12.88. Meaning, the purchaser of the share is investing $12.88 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.03%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 25.7%, now sitting on 49.27B for the twelve trailing months.

Moving Average

Harmony Gold Mining Company Limited’s worth is way higher than its 50-day moving average of $4.42 and way above its 200-day moving average of $4.20.

Yearly Top and Bottom Value

Harmony Gold Mining Company Limited’s stock is valued at $5.41 at 01:32 EST, under its 52-week high of $5.47 and way higher than its 52-week low of $2.93.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Oct 11, 2023, the estimated forward annual dividend rate is 0.05 and the estimated forward annual dividend yield is 0.97%.

More news about Harmony Gold Mining Company Limited.

6. Hudson Pacific Properties (HPP) – 14.08%

Hudson Pacific is a real estate investment trust with a portfolio of office and studio properties totaling nearly 19 million square feet, including land for development. Focused on premier West Coast epicenters of innovation, media and technology, its anchor tenants include Fortune 500 and leading growth companies such as Netflix, Google, Square, Uber, NFL Enterprises and more. Hudson Pacific is publicly traded on the NYSE under the symbol HPP, and listed as a component of the S&P MidCap 400 Index.

NYSE ended the session with Hudson Pacific Properties rising 14.08% to $5.67 on Thursday while NYSE rose 0.2% to $15,763.72.

Earnings Per Share

As for profitability, Hudson Pacific Properties has a trailing twelve months EPS of $-0.75.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -2.29%.

Volume

Today’s last reported volume for Hudson Pacific Properties is 5193390 which is 33.92% above its average volume of 3877940.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Hudson Pacific Properties’s EBITDA is 6.03.

Moving Average

Hudson Pacific Properties’s worth is under its 50-day moving average of $5.90 and under its 200-day moving average of $6.26.

More news about Hudson Pacific Properties.

7. Hannon Armstrong Sustainable Infrastructure Capital (HASI) – 13.64%

Hannon Armstrong Sustainable Infrastructure Capital, Inc. provides capital and services to the energy efficiency, renewable energy, and other sustainable infrastructure markets in the United States. The company's projects include building or facility that reduce energy usage or cost through the use of solar generation and energy storage or energy efficiency improvements, including heating, ventilation, and air conditioning systems (HVAC), as well as lighting, energy controls, roofs, windows, building shells, and/or combined heat and power systems. It also focuses in the areas of grid connected projects that deploy cleaner energy sources, such as solar and wind to generate power; and other sustainable infrastructure projects, including upgraded transmission or distribution systems, water and storm water infrastructures, and other projects. The company qualifies as a real estate investment trust for U.S. federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 1981 and is headquartered in Annapolis, Maryland.

NYSE ended the session with Hannon Armstrong Sustainable Infrastructure Capital rising 13.64% to $22.50 on Thursday while NYSE rose 0.2% to $15,763.72.

Earnings Per Share

As for profitability, Hannon Armstrong Sustainable Infrastructure Capital has a trailing twelve months EPS of $0.36.

PE Ratio

Hannon Armstrong Sustainable Infrastructure Capital has a trailing twelve months price to earnings ratio of 62.5. Meaning, the purchaser of the share is investing $62.5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.11%.

More news about Hannon Armstrong Sustainable Infrastructure Capital.

8. V.F. Corporation (VFC) – 12.4%

V.F. Corporation, together with its subsidiaries, engages in the design, procurement, marketing, and distribution of branded lifestyle apparel, footwear, and related products for men, women, and children in the Americas, Europe, and the Asia-Pacific. It operates through three segments: Outdoor, Active, and Work. The company offers outdoor, merino wool and other natural fibers-based, lifestyle, and casual apparel; footwear; equipment; accessories; outdoor-inspired, performance-based, youth culture/action sports-inspired, streetwear, and protective work footwear; handbags, luggage, backpacks, and totes; and work and work-inspired lifestyle apparel and footwear. It provides its products under The North Face, Timberland, Smartwool, Icebreaker, Altra, Vans, Supreme, Kipling, Napapijri, Eastpak, JanSport, Dickies, and Timberland PRO brand names. The company sells its products primarily to specialty stores, department stores, national chains, and mass merchants, as well as sells through direct-to-consumer operations, including retail stores, concession retail stores, and e-commerce sites, and other digital platforms. V.F. Corporation was founded in 1899 and is headquartered in Denver, Colorado.

NYSE ended the session with V.F. Corporation jumping 12.4% to $17.50 on Thursday while NYSE rose 0.2% to $15,763.72.

Earnings Per Share

As for profitability, V.F. Corporation has a trailing twelve months EPS of $-0.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.86%.

Volume

Today’s last reported volume for V.F. Corporation is 8200120 which is 5.97% below its average volume of 8721450.

More news about V.F. Corporation.

9. MicroVision (MVIS) – 11.68%

MicroVision, Inc. develops and sells lidar sensors used in automotive safety and autonomous driving applications. Its laser beam scanning technology is based on micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company also develops micro-display concepts and designs for head-mounted augmented reality (AR) headsets, as well as 1440i MEMS module supporting AR headsets; interactive display solutions for the smart speakers market; and Consumer Lidar used in smart home systems. In addition, it develops 1st Generation LRL module. The company sells its products primarily to original equipment manufacturers and original design manufacturers. MicroVision, Inc. was founded in 1993 and is headquartered in Redmond, Washington.

NASDAQ ended the session with MicroVision rising 11.68% to $2.39 on Thursday while NASDAQ rose 0.07% to $14,103.84.

Earnings Per Share

As for profitability, MicroVision has a trailing twelve months EPS of $-0.43.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -83.29%.

Yearly Top and Bottom Value

MicroVision’s stock is valued at $2.39 at 01:32 EST, way below its 52-week high of $8.20 and way above its 52-week low of $1.82.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MicroVision’s EBITDA is -36.65.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 1.43%.

More news about MicroVision.

10. Catalent (CTLT) – 11.22%

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

NYSE ended the session with Catalent rising 11.22% to $39.51 on Thursday while NYSE rose 0.2% to $15,763.72.

Earnings Per Share

As for profitability, Catalent has a trailing twelve months EPS of $-1.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.93%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Catalent’s stock is considered to be overbought (>=80).

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 138.2% and a negative 92.5%, respectively.

Volatility

Catalent’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.99%, a negative 1.68%, and a positive 1.99%.

Catalent’s highest amplitude of average volatility was 0.99% (last week), 2.99% (last month), and 1.99% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Catalent’s EBITDA is -129.42.

More news about Catalent.

Losers Today

1. Eli Lilly and Company (LLY) – -3.85%

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

NYSE ended the session with Eli Lilly and Company sliding 3.85% to $587.33 on Thursday while NYSE jumped 0.2% to $15,763.72.

Earnings Per Share

As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.5.

PE Ratio

Eli Lilly and Company has a trailing twelve months price to earnings ratio of 106.79. Meaning, the purchaser of the share is investing $106.79 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 46.46%.

Yearly Top and Bottom Value

Eli Lilly and Company’s stock is valued at $587.33 at 01:32 EST, under its 52-week high of $629.97 and way above its 52-week low of $309.20.

Revenue Growth

Year-on-year quarterly revenue growth grew by 36.8%, now sitting on 32.07B for the twelve trailing months.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Nov 13, 2023, the estimated forward annual dividend rate is 4.52 and the estimated forward annual dividend yield is 0.76%.

More news about Eli Lilly and Company.

2. TJX Companies (TJX) – -3.83%

The TJX Companies, Inc., together with its subsidiaries, operates as an off-price apparel and home fashions retailer in the United States, Canada, Europe, and Australia. It operates through four segments: Marmaxx, HomeGoods, TJX Canada, and TJX International. The company sells family apparel, including footwear and accessories; home fashions, such as home basics, furniture, rugs, lighting products, giftware, soft home products, decorative accessories, tabletop, and cookware, as well as expanded pet, and gourmet food departments; jewelry and accessories; and other merchandise. The TJX Companies, Inc. was incorporated in 1962 and is headquartered in Framingham, Massachusetts.

NYSE ended the session with TJX Companies sliding 3.83% to $88.96 on Thursday, after two sequential sessions in a row of gains. NYSE jumped 0.2% to $15,763.72, after three sequential sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, TJX Companies has a trailing twelve months EPS of $3.41.

PE Ratio

TJX Companies has a trailing twelve months price to earnings ratio of 26.09. Meaning, the purchaser of the share is investing $26.09 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.32%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

TJX Companies’s EBITDA is 2.1.

Yearly Top and Bottom Value

TJX Companies’s stock is valued at $88.96 at 01:32 EST, below its 52-week high of $93.78 and way higher than its 52-week low of $69.93.

Previous days news about TJX Companies

• Things to consider before the TJX companies (tjx) Q3 earnings. According to Zacks on Tuesday, 14 November, "Our proven model predicts an earnings beat for The TJX Companies this time around. ", "Yet, The TJX Companies has been witnessing incremental wage costs and supply-chain costs. "

More news about TJX Companies.

3. Ivy High Income Opportunities Fund (IVH) – -3.54%

Ivy Funds – Ivy High Income Opportunities Fund is a closed ended fixed income mutual fund launched and managed by Ivy Investment Management Company. The fund invests in fixed income markets across the globe. It seeks to invest in securities of companies operating across diversified sectors. The fund primarily invests in high-yield corporate bonds of various maturities, secured loans, and other corporate fixed-income instruments, which are rated below investment grade (below Baa3 by Moody's or below BBB- by either S&P or Fitch). Ivy Funds – Ivy High Income Opportunities Fund was formed on May 29, 2013 and is domiciled in the United States.

NYSE ended the session with Ivy High Income Opportunities Fund dropping 3.54% to $11.18 on Thursday, after four sequential sessions in a row of losses. NYSE jumped 0.2% to $15,763.72, after three consecutive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Yearly Top and Bottom Value

Ivy High Income Opportunities Fund’s stock is valued at $11.18 at 01:32 EST, below its 52-week high of $12.38 and above its 52-week low of $10.42.

More news about Ivy High Income Opportunities Fund.

4. Vertex Pharmaceuticals (VRTX) – -3.46%

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Vertex Pharmaceuticals falling 3.46% to $357.16 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.07% to $14,103.84, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.32.

PE Ratio

Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 26.81. Meaning, the purchaser of the share is investing $26.81 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.49%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Vertex Pharmaceuticals’s stock is considered to be oversold (<=20).

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Jan 1, 1970, the estimated forward annual dividend yield is 1.55%.

Moving Average

Vertex Pharmaceuticals’s value is below its 50-day moving average of $359.06 and higher than its 200-day moving average of $336.85.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.4%, now sitting on 9.65B for the twelve trailing months.

More news about Vertex Pharmaceuticals.

5. Sumitomo Mitsui (SMFG) – -3.03%

Sumitomo Mitsui Financial Group, Inc., together with its subsidiaries, provides banking, leasing, securities, credit card, and consumer finance services in Japan, the Americas, Europe, the Middle East, Asia, and Oceania. It operates through Wholesale Business Unit, Retail Business Unit, Global Business Unit, and Global Markets Business Unit segments. The company was incorporated in 2002 and is headquartered in Tokyo, Japan.

NYSE ended the session with Sumitomo Mitsui sliding 3.03% to $9.48 on Thursday, following the last session’s upward trend. NYSE rose 0.2% to $15,763.72, after three consecutive sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Sumitomo Mitsui has a trailing twelve months EPS of $0.79.

PE Ratio

Sumitomo Mitsui has a trailing twelve months price to earnings ratio of 12. Meaning, the purchaser of the share is investing $12 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.2%.

Volatility

Sumitomo Mitsui’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.77%, a negative 0.22%, and a positive 1.27%.

Sumitomo Mitsui’s highest amplitude of average volatility was 0.98% (last week), 1.40% (last month), and 1.27% (last quarter).

Moving Average

Sumitomo Mitsui’s value is under its 50-day moving average of $9.77 and above its 200-day moving average of $8.83.

More news about Sumitomo Mitsui.

6. Full House Resorts (FLL) – -2.72%

Full House Resorts, Inc. owns, develops, invests in, operates, manages, and leases casinos, and related hospitality and entertainment facilities in the United States. The company owns and operates the Silver Slipper Casino and Hotel in Hancock County, Mississippi; Bronco Billy's Casino and Hotel in Cripple Creek, Colorado; Rising Star Casino Resort in Rising Sun, Indiana; Stockman's Casino in Fallon, Nevada; Grand Lodge Casino in Incline Village, Nevada; and American Place / The Temporary in Waukegan, Illinois. It also operates online sports wagering websites. Full House Resorts, Inc. was incorporated in 1987 and is headquartered in Las Vegas, Nevada.

NASDAQ ended the session with Full House Resorts dropping 2.72% to $5.01 on Thursday, following the last session’s upward trend. NASDAQ rose 0.07% to $14,103.84, following the last session’s upward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Full House Resorts has a trailing twelve months EPS of $-0.56.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.8%.

Moving Average

Full House Resorts’s value is way higher than its 50-day moving average of $4.31 and way below its 200-day moving average of $6.42.

Yearly Top and Bottom Value

Full House Resorts’s stock is valued at $5.01 at 01:32 EST, way under its 52-week high of $10.13 and way higher than its 52-week low of $3.40.

Volume

Today’s last reported volume for Full House Resorts is 87472 which is 48.41% below its average volume of 169562.

More news about Full House Resorts.

7. Zai Lab (ZLAB) – -2.7%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab falling 2.7% to $27.58 on Thursday while NASDAQ jumped 0.07% to $14,103.84.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.29%.

Yearly Top and Bottom Value

Zai Lab’s stock is valued at $27.58 at 01:32 EST, way below its 52-week high of $49.81 and way higher than its 52-week low of $22.35.

More news about Zai Lab.

8. BeiGene (BGNE) – -2.58%

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

NASDAQ ended the session with BeiGene dropping 2.58% to $196.37 on Thursday while NASDAQ jumped 0.07% to $14,103.84.

Earnings Per Share

As for profitability, BeiGene has a trailing twelve months EPS of $-9.23.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -38.07%.

Volatility

BeiGene’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.24%, a positive 0.53%, and a positive 2.54%.

BeiGene’s highest amplitude of average volatility was 3.60% (last week), 2.92% (last month), and 2.54% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 74.3%, now sitting on 1.81B for the twelve trailing months.

More news about BeiGene.

9. AMC (AMC) – -2.55%

AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. AMC Entertainment Holdings, Inc. was founded in 1920 and is headquartered in Leawood, Kansas.

NYSE ended the session with AMC falling 2.55% to $7.86 on Thursday, following the last session’s upward trend. NYSE rose 0.2% to $15,763.72, after three successive sessions in a row of gains, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, AMC has a trailing twelve months EPS of $-3.

Volatility

AMC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 8.66%, a negative 0.94%, and a positive 7.40%.

AMC’s highest amplitude of average volatility was 8.66% (last week), 4.33% (last month), and 7.40% (last quarter).

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Mar 5, 2020, the estimated forward annual dividend rate is 0.12 and the estimated forward annual dividend yield is 2.12%.

Sales Growth

AMC’s sales growth is 28% for the current quarter and 14.6% for the next.

Previous days news about AMC

• Bears are losing control over AMC entertainment (amc), here's why it's a 'buy' now. According to Zacks on Tuesday, 14 November, "An upward trend in earnings estimate revisions that AMC has been witnessing lately can certainly be considered a bullish indicator on the fundamental side. ", "So, for the shares of AMC Entertainment, a Zacks Rank of 2 is a more conclusive fundamental indication of a potential turnaround."

More news about AMC.

10. Novo Nordisk A/S (NVO) – -2.54%

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NYSE ended the session with Novo Nordisk A/S falling 2.54% to $96.68 on Thursday while NYSE rose 0.2% to $15,763.72.

Earnings Per Share

As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.4.

PE Ratio

Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 40.28. Meaning, the purchaser of the share is investing $40.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 81.54%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 57.8% and 51.2%, respectively.

Volume

Today’s last reported volume for Novo Nordisk A/S is 3441370 which is 24.19% below its average volume of 4539670.

Moving Average

Novo Nordisk A/S’s value is above its 50-day moving average of $94.73 and way above its 200-day moving average of $82.24.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Novo Nordisk A/S’s EBITDA is 13.45.

More news about Novo Nordisk A/S.

Stay up to date with our winners and losers daily report